Blood inflammatory markers combined with tumor markers for differentiating benign prostatic hyperplasia from prostate cancer
Blood inflammatory markers, particularly AISI, in combination with conventional biomarkers, offer enhanced diagnostic accuracy for differentiating BPH from PCa, representing a non-invasive and cost-effective approach for clinical decision-making.
Authors
- Jia Keke
- Xiaoli Hou
- Zeqiang Liu
- Xinji Yang
- Peng Du
Institutions
- King University (US)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Peking University Third Hospital (CN)
- Ministry of Education (ET)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-02-04
- DOI
- https://doi.org/10.3389/fmed.2026.1730818
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wu Jieping Medical Foundation